Lomond Therapeutics develops small molecule therapies targeting escape mutations in hematological cancers, addressing the challenge of treatment resistance in both hematological and solid malignancies. The company aims to deliver first and best-in-class medicines that improve patient outcomes by effectively overcoming these resistant mutations.
Funding
$44M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Hematological cancers often develop resistance to treatment due to escape mutations, which limit the effectiveness of existing therapies. These mutations pose a significant challenge in both hematological and solid malignancies, leading to poor patient outcomes.
Solution
Lomond Therapeutics is developing small molecule therapies specifically designed to target these escape mutations in hematological cancers. By focusing on resistant mutations, the company aims to deliver first-in-class and best-in-class medicines that can effectively overcome treatment resistance. These therapies are intended to improve patient outcomes by providing more effective treatment options for hematological malignancies. Lomond Therapeutics is a development stage spinout from Eilean Therapeutics, a biopharma company targeting resistant mutations in hematological and solid cancer malignancies.
Target Audience
The primary target audience includes patients with hematological cancers who have developed resistance to existing treatments, as well as the healthcare professionals who treat them.
Features
- Small molecule therapies designed to target escape mutations.
- Focus on hematological cancers with potential application in solid malignancies.
- Aims to deliver first-in-class and best-in-class medicines.